CCL2 and amyotrophic lateral sclerosis: Namely, we tested the null hypothesis of no difference between healthy controls and ALS against the alternatives of overexpression of benzoic and hexadecanoic acids and TTV in ALS and underexpression of valeric acid, MCP1, and MIP1-α in ALS.